Significance of gut-blood barrier in health and disease

Tomasz Huc, Kinga Pham, Janusz Skrzypecki, Marcin Ufnal


The gut microbiota produces a number of biologically active compounds that may have both, positive and negative effects on health. To enter the circulation, microbiota-derived molecules need to pass the gut-blood barrier (GBB), a complex multi-layer system that prevents the free passage form the gut lumen to the blood. The integrity and permeability of the GBB depends on numerous factors, and may be disturbed in gastrointestinal, metabolic, cardiovascular and other diseases. An increased permeability of the GBB results in easier access of gut-derived molecules to the circulation. This may exert a significant effect on the course of the underlying disease and may alter functioning of various organs. Here, we discuss physiological significance of the GBB and available methods of assessing the GBB permeability.


Intestinal microbiome; Gut-blood barrier; Heart failure; Diabetes; Intestinal barrier

Full Text:



Macfarlane GT, Macfarlane S. Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria. Scand J Gastroenterol Suppl. 1997; 222: 3-9.

Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016; 14(1): 20-32.

Reinoso Webb C, Koboziev I, Furr KL, Grisham MB. Protective and pro-inflammatory roles of intestinal bacteria. Pathophysiology. 2016; 23(2): 67-80.

Cummings JH, Macfarlane GT. Role of intestinal bacteria in nutrient metabolism. JPEN J Parenter Enteral Nutr. 1997; 21(6): 357-365.

Zhang YJ, Li S, Gan RY, Zhou T, Xu DP, Li HB. Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015; 16(4): 7493-7519.

Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011; 8(2): 110-120.

Gaci N, Borrel G, Tottey W, O'Toole PW, Brugere JF. Archaea and the human gut: new beginning of an old story. World J Gastroenterol. 2014; 20(43): 16062-16078.

Polhemus DJ, Lefer DJ. Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. Circ Res. 2014; 114(4): 730-737.

Sikora M, Drapala A, Ufnal M. Exogenous hydrogen sulfide causes different hemodynamic effects in normotensive and hypertensive rats via neurogenic mechanisms. Pharmacol Rep. 2014; 66(5): 751-758.

Tomas-Barberan FA, Andres-Lacueva C. Polyphenols and health: current state and progress. J Agric Food Chem. 2012; 60(36): 8773-8775.

Russell WR, Hoyles L, Flint HJ, Dumas ME. Colonic bacterial metabolites and human health. Curr Opin Microbiol. 2013; 16(3): 246-254.

Ufnal M, Zadlo A, Ostaszewski R. TMAO: A small molecule of great expectations. Nutrition. 2015; 31(11-12): 1317-1323.

Ufnal M, Jazwiec R, Dadlez M, Drapala A, Sikora M, Skrzypecki J. Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can J Cardiol. 2014; 30(12): 1700-1705.

Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013; 19(5): 576-585.

Canny GO, McCormick BA. Bacteria in the intestine, helpful residents or enemies from within? Infect Immun. 2008; 76(8): 3360-3373.

Riddington DW, Venkatesh B, Boivin CM, Bonser RS, Elliott TS, Marshall T, et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA. 1996; 275(13): 1007-1012.

Keita AV, Soderholm JD. The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol Motil. 2010; 22(7): 718-733.

Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes. 2012; 2012: 879151.

Lopetuso LR, Scaldaferri F, Bruno G, Petito V, Franceschi F, Gasbarrini A. The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Eur Rev Med Pharmacol Sci. 2015; 19(6): 1068-1076.

Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability - a new target for disease prevention and therapy. BMC Gastroenterol. 2014; 14: 189.

Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol. 2003; 18(5): 479-497.

Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014; 14(3): 141-153.

Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 2009; 1165: 294-300.

Dignass AU, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology. 1993; 105(5): 1323-1332.

Berkes J, Viswanathan VK, Savkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut. 2003; 52(3): 439-451.

Kucharzik T, Lugering N, Rautenberg K, Lugering A, Schmidt MA, Stoll R, et al. Role of M cells in intestinal barrier function. Ann N Y Acad Sci. 2000; 915: 171-183.

Andersen K, Kesper MS, Marschner JA, Konrad L, Ryu M, Kumar Vr S, et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol. 2016: ASN.2015111285.

Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001; 121(3): 580-591.

Goto Y, Kiyono H. Epithelial barrier: an interface for the cross-communication between gut flora and immune system. Immunol Rev. 2012; 245(1): 147-163.

Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol. 2008; 22(3): 391-409.

Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens. 2012; 21(6): 587-592.

Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2006; 290(3): G496-504.

Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005; 280(43): 36099-36109.

Krack A, Richartz BM, Gastmann A, Greim K, Lotze U, Anker SD, et al. Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. Eur J Heart Fail. 2004; 6(4): 403-407.

Bohlen HG. Intestinal microvascular adaptation during maturation of spontaneously hypertensive rats. Hypertension 1983; 5(5): 739-745.

Sasor A, Ohlsson B. Microangiopathy is common in submucosal vessels of the colon in patients with diabetes mellitus. Rev Diabet Stud 2014; 11(2): 175-180.

Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448(7152): 427-434.

McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009; 15(1) :100-113.

Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol. 2008; 14(3): 401-407.

Duckworth CA, Watson AJ. Analysis of epithelial cell shedding and gaps in the intestinal epithelium. Methods Mol Biol 2011; 763: 105-114.

Ventura MT, Polimeno L, Amoruso AC, Gatti F, Annoscia E, Marinaro M, et al. Intestinal permeability in patients with adverse reactions to food. Dig Liver Dis. 2006; 38(10): 732-736.

Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009; 124(1): 3-20; quiz 1-2.

Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010; 125(2 Suppl 2): S116-125.

Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol. 1997; 99(2): 179-185.

Heyman M. Gut barrier dysfunction in food allergy. Eur J Gastroenterol Hepatol. 2005; 17(12): 1279-1285.

Sampson HA. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol. 1999; 103(5 Pt 1): 717-728.

Gomes AC, Bueno AA, de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J. 2014; 13: 60.

Vaarala O, Atkinson MA, Neu J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. 2008; 57(10): 2555-2562.

Sandek A, Swidsinski A, Schroedl W, Watson A, Valentova M. et al. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol. 2014; 64(11): 1092-1102.

Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323(4): 236-241.

Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000; 102(25): 3060-3067.

Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol. 2008; 125(2): 240-245.

Rahman SH, Ammori BJ, Holmfield J, Larvin M, McMahon MJ. Intestinal hypoperfusion contributes to gut barrier failure in severe acute pancreatitis. J Gastrointest Surg. 2003; 7(1): 26-35.

Ohri SK, Somasundaram S, Koak Y, Macpherson A, Keogh BE, Taylor KM, et al. The effect of intestinal hypoperfusion on intestinal absorption and permeability during cardiopulmonary bypass. Gastroenterology. 1994; 106(2): 318-323.

Senthil M, Brown M, Xu DZ, Lu Q, Feketeova E, Deitch EA. Gut-lymph hypothesis of systemic inflammatory response syndrome/multiple-organ dysfunction syndrome: validating studies in a porcine model. J Trauma. 2006; 60(5): 958-965.

Fries W, Muja C, Crisafulli C, Cuzzocrea S, Mazzon E. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol. 2008; 294(4): G938-947.

Lambert GP. Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects. J Anim Sci. 2009; 87(14 Suppl): E101-108.

Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol. 2008; 125(2): 240-245.

King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996; 25(2): 144-149.

Alverdy JC, Spitz J, Hecht G, Ghandi S. Causes and consequences of bacterial adherence to mucosal epithelia during critical illness. New Horiz. 1994; 2(2): 264-272.

Anderson AD, Jain PK, Fleming S, Poon P, Mitchell CJ, MacFie J. Evaluation of a triple sugar test of colonic permeability in humans. Acta Physiol Scand. 2004; 182(2): 171-177.

Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci. 2007; 10(3): 368-379.

Lozoya-Agullo I, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Merino-Sanjuan M, Bermejo M. In situ perfusion model in rat colon for drug absorption studies: comparison with small intestine and Caco-2 cell model. J Pharm Sci. 2015; 104(9): 3136-3145.

Oberle RL, Moore TJ, Krummel DA. Evaluation of mucosal damage of surfactants in rat jejunum and colon. J Pharmacol Toxicol Methods. 1995; 33(2): 75-81.

Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006; 23(8): 1675-1686.

Rupani B, Caputo FJ, Watkins AC, Vega D, Magnotti LJ, Lu Q, et al. Relationship between disruption of the unstirred mucus layer and intestinal restitution in loss of gut barrier function after trauma hemorrhagic shock. Surgery. 2007; 141(4): 481-489.

Saito T, Unno N, Yamamoto N, Inuzuka K, Sagara D, Suzuki M, et al. Intraperitoneal administration of hyperbarically oxygenated perfluorochemical enhances preservation of intestinal mucosa against ischemia/reperfusion injury. Shock. 2006; 26(6): 620-624.

Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol. 1999; 13(2): 154-168.

Acra SA, Ghishan FK. Methods of investigating intestinal transport. JPEN J Parenter Enteral Nutr. 1991; 15(3): 93S-98S.

Lautenschlager I, Frerichs I, Dombrowsky H, Sarau J, Goldmann T, Zitta K, et al. Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis. PLoS One. 2015; 10(3): e0120802.

Li M, Si L, Pan H, Rabba AK, Yan F, Qiu J, et al. Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. Int J Pharm. 2011; 403(1-2): 37-45.

Barthe L, Woodley JF, Kenworthy S, Houin G. An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine. Eur J Drug Metab Pharmacokinet. 1998; 23(2): 313-323.

Li H, Sheppard DN, Hug MJ. Transepithelial electrical measurements with the Ussing chamber. J Cyst Fibros. 2004; 3 Suppl 2: 123-126.

Clarke LL. A guide to Ussing chamber studies of mouse intestine. Am J Physiol Gastrointest Liver Physiol. 2009; 296(6): G1151-1166.


  • There are currently no refbacks.